Old Web
English
Sign In
Acemap
>
authorDetail
>
Honeylet Wortman-Vayn
Honeylet Wortman-Vayn
Bristol-Myers Squibb
Internal medicine
Multiple myeloma
Medicine
Oncology
CAR T-cell therapy
2
Papers
6
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma.
2021
Journal of Clinical Oncology
Saad Z. Usmani
Jesus G. Berdeja
Anna Truppel-Hartmann
Yizhou Fei
Honeylet Wortman-Vayn
Suresh Shelat
Steven Novick
Nina Shah
Show All
Source
Cite
Save
Citations (1)
KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma
2020
Blood
Saad Z. Usmani
Jesus G. Berdeja
Anna Truppel-Hartmann
Marie-Laure Casadebaig
Honeylet Wortman-Vayn
Suresh Shelat
Steven Novick
Nina Shah
Show All
Source
Cite
Save
Citations (5)
1